Clinical Trial Update: Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of temozolomide and atezolizumab for second-line treatment of metastatic or recurrent small cell lung cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab)
• Temodar (Temozolomide)

Snippet

Sponsor: Dwight Owen | Conditions: Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 2 | Status: RECRUITING